Bioactive Materials,
Journal Year:
2023,
Volume and Issue:
32, P. 445 - 472
Published: Oct. 26, 2023
Effective
tumor
treatment
depends
on
optimizing
drug
penetration
and
accumulation
in
tissue
while
minimizing
systemic
toxicity.
Nanomedicine
has
emerged
as
a
key
solution
that
addresses
the
rapid
clearance
of
free
drugs,
but
achieving
deep
into
solid
tumors
remains
elusive.
This
review
discusses
various
strategies
to
enhance
penetration,
including
manipulation
microenvironment,
exploitation
both
external
internal
stimuli,
pioneering
nanocarrier
surface
engineering,
development
innovative
tactics
for
active
penetration.
One
outstanding
strategy
is
organelle-affinitive
transfer,
which
exploits
unique
properties
specific
cell
organelles
heralds
potentially
transformative
approach
transcellular
transfer
Rigorous
models
are
essential
evaluate
efficacy
these
strategies.
The
patient-derived
xenograft
(PDX)
model
gaining
traction
bridge
between
laboratory
discovery
clinical
application.
However,
journey
from
bench
bedside
nanomedicines
fraught
with
challenges.
Future
efforts
should
prioritize
deepening
our
understanding
nanoparticle-tumor
interactions,
re-evaluating
EPR
effect,
exploring
novel
nanoparticle
transport
mechanisms.
Journal of Nanobiotechnology,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: Jan. 13, 2023
Macrophage
polarization
determines
the
production
of
cytokines
that
fuel
initiation
and
evolution
rheumatoid
arthritis
(RA).
Thus,
modulation
macrophage
might
represent
a
potential
therapeutic
strategy
for
RA.
However,
coordinated
macrophages
in
synovium
synovial
fluid
has
not
been
achieved
thus
far.
Herein,
we
develop
biomimetic
ApoA-I
mimetic
peptide-modified
neutrophil
membrane-wrapped
F127
polymer
(R4F-NM@F127)
targeted
drug
delivery
during
RA
treatment.
Due
to
high
expression
adhesion
molecules
chemokine
receptors
on
neutrophils,
membrane
coating
can
endow
nanocarrier
with
synovitis-targeting
ability,
subsequent
recruitment
under
chemotactic
effects
IL-8.
Moreover,
R4F
peptide
modification
further
endows
ability
target
SR-B1
receptor,
which
is
highly
expressed
fluid.
Long-term
vivo
imaging
shows
R4F-NM@F127
preferentially
accumulates
inflamed
joints
engulfed
by
macrophages.
After
loading
anti-inflammatory
celastrol
(Cel),
R4F-NM@F127-Cel
significant
reduction
hepatotoxicity,
effectively
inhibits
inflammation
alleviates
joint
damage
reprogramming
polarization.
our
results
highlight
as
promising
option
treatment
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
36(7)
Published: Sept. 15, 2023
Abstract
Brain
diseases,
such
as
brain
tumors,
neurodegenerative
cerebrovascular
and
injuries,
are
caused
by
various
pathophysiological
changes,
which
pose
a
serious
health
threat.
disorders
often
difficult
to
treat
due
the
presence
of
blood–brain
barrier
(BBB).
Biomimetic
nanovesicles
(BNVs),
including
endogenous
extracellular
vesicles
(EVs)
derived
from
cells
artificial
nanovesicles,
possess
ability
penetrate
BBB
thus
can
be
utilized
for
drug
delivery
brain.
BNVs,
especially
EVs,
widely
distributed
in
body
fluids
usually
carry
disease‐related
signal
molecules
proteins,
RNA,
DNA,
may
also
analyzed
understand
etiology
pathogenesis
diseases.
This
review
covers
exhaustive
classification
characterization
BNVs
roles
involved
emphatically
focuses
on
nanotechnology‐integrated
disease
theranostics,
diagnosis
strategies
precise
therapeutic
regulations
(e.g.,
immunity
regulation,
disordered
protein
clearance,
anti‐neuroinflammation,
neuroregeneration,
angiogenesis,
gut–brain
axis
regulation).
The
remaining
challenges
future
perspectives
regarding
treatment
diseases
discussed
outlined.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(16), P. 15893 - 15904
Published: Aug. 11, 2023
Inflammatory
bowel
disease
(IBD)
is
a
chronic
gastrointestinal
tract
disorder
characterized
by
uncontrolled
inflammatory
responses
to
the
disrupted
intestinal
epithelial
barrier
and
gut
microbiome
dysbiosis.
Currently
available
small-molecule
immunosuppressive
agents
anticytokine
biologics
show
limited
potency,
mainly
due
complexity
of
network
involved
in
IBD.
Here,
we
develop
an
oral
formulation
macrophage
membrane-coated
nanoparticles
capsulated
enteric
polymer-coated
gelatin
capsules
(denoted
"cp-MΦ-NPs")
for
IBD
treatment.
The
protect
from
gastric
degradation
allow
targeted
delivery
colon.
At
inflamed
colon,
cp-MΦ-NPs
act
as
decoys
that
bind
neutralize
pro-inflammatory
cytokines.
vivo
treatment
efficacy
tested
mouse
model
dextran
sulfate
sodium-induced
colitis.
In
both
prophylactic
delayed
regimens,
significantly
alleviates
severity,
reflected
reduced
inflammation
restoration.
Overall,
provide
biomimetic
nanomedicine
strategy
Advanced Functional Materials,
Journal Year:
2024,
Volume and Issue:
34(23)
Published: Feb. 15, 2024
Abstract
Nanodrug
delivery
systems
(NDDSs)
for
the
treatment
of
periodontitis
remain
a
significant
clinical
challenge.
The
low
biocompatibility,
singular
effect,
and
lack
disease
specificity
conventional
nanoparticles
limit
their
biomedical
application.
Recent
studies
have
highlighted
pivotal
role
cell
membrane‐coated
nanotechnology
in
anti‐inflammatory
strategies
due
to
its
improved
biocompatibility
superior
biointerface
properties.
Herein,
combined
with
pathological
heterogeneity
revealed
by
bioinformatics
analysis,
this
study
develops
novel
nanoparticle
composed
two
elements:
minocycline‐loaded
polydopamine
(PM)
cRGD‐modified
membrane
(RCM).
vitro
results
indicate
that
PM@RCM
rescues
impaired
human
periodontal
ligament
stem
cells
through
antioxidant,
anti‐ferroptosis,
anti‐inflammatory,
pro‐osteogenic
effects,
exhibits
favorable
antibacterial
bioactivity.
vivo
further
reveal
promotes
tissue
regeneration
remodeled
homeostasis
mice.
Collectively,
these
findings
highlight
unique
changes
periodontitis.
Moreover,
NDDS
developed
study,
which
leverages
excellent
natural
properties
versatility
cores,
provides
promising
strategy
Journal of Controlled Release,
Journal Year:
2024,
Volume and Issue:
367, P. 300 - 315
Published: Jan. 30, 2024
Nanoparticle
formulations
blending
optical
imaging
contrast
agents
and
therapeutics
have
been
a
cornerstone
of
preclinical
theranostic
applications.
However,
nanoparticle-based
theranostics
clinical
translation
faces
challenges
on
reproducibility,
brightness,
photostability,
biocompatibility,
selective
tumor
targeting
penetration.
In
this
study,
we
integrate
multimodal
within
cancer
cell-derived
nanovesicles,
leading
to
biomimetic
bright
optotheranostics
for
monitoring
metastasis.
Upon
NIR
light
irradiation,
the
engineered
enables
deep
visualization
precise
localization
metastatic
lung,
liver,
solid
breast
tumors
along
with
ablation.
Metastatic
nanovesicles
(∼80
±
5
nm)
are
encapsulate
(emissive
organic
dye
gold
nanoparticles)
therapeutic
(anticancer
drug
doxorubicin
photothermally
active
indocyanine
green
dye).
Systemic
administration
optotheranostic
nanoparticles
shows
escape
from
mononuclear
phagocytic
clearance
(i)
rapid
accumulation
(3
h)
retention
(up
168
h),
(ii)
real-time
(iii)
3-fold
image-guided
reduction.
These
findings
supported
by
an
improvement
X-ray,
fluorescence,
photoacoustic
signals
while
demonstrating
reduction
(201
mm3)
in
comparison
single
therapies
that
includes
chemotherapy
(134
mm3),
photodynamic
therapy
(72
photothermal
(88
mm3).
The
proposed
innovative
platform
opens
new
avenues
improve
diagnosis
treatment
outcomes
allowing
monitorization
metastasis,
imaging,
delivering
synergistic
at
site.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Feb. 19, 2024
Background
Atherosclerosis
and
cardiovascular
diseases
are
significantly
affected
by
low-grade
chronic
inflammation.
As
a
new
inflammatory
marker,
the
systemic
inflammation
response
index
(SIRI)
has
been
demonstrated
to
be
associated
with
several
disease
prognoses.
This
study
aimed
investigate
prognostic
impact
of
SIRI
in
individuals
having
ischemic
heart
failure
(IHF)
following
percutaneous
coronary
intervention
(PCI).
Methods
observational,
retrospective
cohort
was
conducted
at
single
site.
Finally,
research
involved
1,963
IHF
who
underwent
PCI,
36-month
follow-up
duration.
Based
on
quartiles,
all
patients
were
classified
into
four
groups.
Major
adverse
events
(MACEs)
primary
outcomes.
Every
element
main
endpoint
appeared
secondary
endpoints:
all-cause
mortality,
non-fatal
myocardial
infarction
(MI),
any
revascularization.
Kaplan–Meier
survival
analysis
assess
incidence
endpoints
across
Multivariate
Cox
proportional
hazards
confirmed
independent
both
endpoints.
The
restricted
cubic
spline
(RCS)
used
nonlinear
association
between
Subgroup
performed
confirm
implications
MACE
different
subgroups.
Results
outcome
much
more
common
higher
SIRI.
curve
another
tool
that
favorable
connection
MACE.
individually
connected
chance
according
multivariate
analyses,
whether
or
not
constant
[SIRI,
per
one−unit
increase,
hazard
ratio
(HR)
1.04,
95%
confidence
interval
(95%
CI)
1.01–1.07,
p
=
0.003]
categorical
variable
[quartile
SIRI,
HR
values
for
quartile
4
1.88
(1.47–2.42),
<0.001,
1
as
reference].
RCS
generally
increased
increased.
A
non-linear
risk
revascularization
(Non-linear
P
<0.001)
observed.
elevated
New
York
Heart
Association
(NYHA)
class
III–IV
(P
interaction
0.005).
Conclusion
In
undergoing
factor
other
factors.
may
represent
novel,
promising,
marker
prognosis
PCI.
Materials Today Bio,
Journal Year:
2025,
Volume and Issue:
31, P. 101534 - 101534
Published: Jan. 29, 2025
The
treatment
and
management
of
kidney
diseases
pose
a
significant
global
burden.
Due
to
the
presence
blood
circulation
barriers
glomerular
filtration
barriers,
drug
therapy
for
faces
challenges
such
as
poor
renal
targeting,
short
half-life,
severe
systemic
side
effects,
severely
hindering
therapeutic
progress.
Therefore,
research
development
kidney-targeted
agents
is
great
clinical
significance.
In
recent
years,
application
nanotechnology
in
field
nephrology
has
shown
potential
revolutionizing
diagnosis
diseases.
Carefully
designed
nanomaterials
can
exhibit
optimal
biological
characteristics,
influencing
various
aspects
circulation,
retention,
excretion.
Rationally
designing
modifying
based
on
anatomical
structure
pathophysiological
environment
achieve
highly
specific
or
nanodrug
delivery
systems
both
feasible
promising.
Based
targeted
diseases,
this
review
discusses
advantages
limitations
current
nanomedicine
summarizes
active/passive
targeting
strategies,
order
further
promote
through
preliminary
summary
previous
studies
future
prospects.
